Active, not recruitingPhase 1NCT05571839
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- PF-08046049(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- UCLA Hematology/Oncology - Administrative Office, Los Angeles, California, United States
- The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States
- UCLA Hematology/Oncology, Los Angeles, California, United States
- UCLA Hematology/ Oncology- Pasadena, Pasadena, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- UCSF Medical Center, Investigational Pharmacy, San Francisco, California, United States
- UCLA Hematology/Oncology - Santa Barbara, Santa Barbara, California, United States
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-up only), Santa Monica, California, United States
- UCLA Hematology - Oncology Clinic - Westlake Village, Westlake Village, California, United States
- Quest Diagnostics Incorporated - Denver, Denver, Colorado, United States
- Presbyterian/St. Lukes Medical Center, Denver, Colorado, United States
- Northwestern Medical Group, Chicago, Illinois, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05571839 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital